Resource impact summary report
This summary report is based on the NICE assumptions used in the resource impact template. Users can amend the 'Inputs and eligible population' and 'Unit costs' worksheets in the template to reflect local data and assumptions.
Recommendation
NICE has recommended vibegron as an option for treating the symptoms of overactive bladder syndrome in adults. It is only recommended if antimuscarinic medicines are not suitable, do not work well enough or have unacceptable side effects.
If people with the condition and their healthcare professional consider vibegron to be 1 of a range of suitable treatments, after discussing the advantages and disadvantages of all the options, the least expensive should be used. Administration costs, dosages, price per dose and commercial arrangements should all be taken into account.
Eligible population for vibegron
Table 1 shows the population who are eligible for vibegron and the number of people who are expected to have vibegron in each of the next 5 years.
| Eligible population and uptake | Current practice | 2024-25 | 2025-26 | 2026-27 | 2027-28 | 2028-29 |
|---|---|---|---|---|---|---|
|
People eligible for vibegron |
268,000 |
270,000 |
273,000 |
276,000 |
278,000 |
281,000 |
|
Uptake for vibegron (%) |
0 |
5 |
7.5 |
10 |
12.5 |
15 |
|
People starting treatment each year |
0 |
13,500 |
7,000 |
7,100 |
7,200 |
7,400 |
|
People continuing treatment each year |
0 |
0 |
13,500 |
20,500 |
27,600 |
34,800 |
|
Total number of people having vibegron each year |
0 |
13,500 |
20,500 |
27,600 |
34,800 |
42,200 |
Treatment options for the eligible population
The comparator treatment for the eligible population is mirabegron, which has the same treatment duration and method of administration. Mirabegron is assumed to have 100% market share currently.
For more information about the treatments, such as dose and average treatment duration, see the resource impact template.
Financial resource impact (cash items)
The key drivers of financial resource impact are:
-
Population growth over time.
-
The price difference between vibegron and mirabegron. Vibegron (£26.68 per pack of 30 tablets) is slightly cheaper than mirabegron (£29.00 per pack of 30 tablets).
-
If no population growth is included, there would be a saving.
Table 2 shows the estimated costs of treatment in each of the next 5 years.
| Cash impact | Current practice | 2024-25 | 2025-26 | 2026-27 | 2027-28 | 2028-29 |
|---|---|---|---|---|---|---|
|
Cash impact (including drug costs; £'000) |
93,215 |
93,737 |
94,451 |
95,200 |
95,894 |
96,623 |
|
Change in cash impact (in year; £'000) |
0 |
522 |
714 |
719 |
724 |
729 |
Population growth causes more people to have the treatment options and creates a cost. The lower price of vibegron than mirabegron means that as people choose vibegron rather than mirabegron, the increasing cost is reduced. There is a net overall cost impact.
The payment mechanism for the technology is determined by the responsible commissioner and depends on the technology being classified as high cost.
We expect the resource impact of implementing the recommendations in England will be around £730,000 per year by year 5. This is due to population growth.
For further analysis or to calculate the financial impact of cash items, see the resource impact template.
Capacity impact
As both treatment options are oral there is no capacity impact. There will be an increase in capacity impact as a result of population growth.
For further analysis or to calculate the financial capacity impact from a commissioner (national) and provider (local) perspective, see the resource impact template.
Key information
| Time from publication to routine commissioning funding |
30 days |
|---|---|
| Programme budgeting category |
PBC 17X Problems of Genito Urinary system |
| Commissioner(s) |
Integrated care boards |
| Provider(s) |
GPs and NHS hospital trusts |
| Pathway position |
Second line |
About this resource impact summary report
This resource impact summary report accompanies the NICE guidance on vibegron for treating symptoms of overactive bladder and should be read with it. See terms and conditions on the NICE website.
ISBN: 978-1-4731-6540-3